Top

Published in:

01-09-2014

A multi-targeted approach to treating bone metastases

Authors: Daniel F. Camacho, Kenneth J. Pienta

Published in: Cancer and Metastasis Reviews | Issue 2-3/2014

Abstract

The treatment of bone-metastatic cancer now takes advantage of the unique biology of this clinical state. The complex interplay between the cancer cells and the bone microenvironment leads to a host of therapeutic targets, with agents in various stages of clinical use or study. Targets include interactions between the cancer cells and osteoclasts, osteoblasts, endothelial cells, stromal cells, hematopoietic progenitor cells, cells of the immune system, and the bone matrix. Efforts at understanding specific mechanisms of drug resistance in the bone are also ongoing. Successful clinical outcomes will be the result of co-targeting and interrupting the various tumor-supportive elements and cooperating pathways at the level of the tumor cell, the primary and metastatic microenvironments, and systemic cancer effects, leading to a “scaled network disruption” to undermine the disease state.

Li, S., Peng, Y., Weinhandl, E. D., Blaes, A. H., Cetin, K., & Chia, V. M., et al. (2012). Estimated number of prevalent cases of metastatic bone disease in the US adult population. Clin Epidemiol, 4, 87–93.

Loberg, R. D., Bradley, D. A., Tomlins, S. A., Chinnaiyan, A. M., & Pienta, K. J. (2007). The lethal phenotype of cancer: the molecular basis of death due to malignancy. CA: A Cancer Journal for Clinicians, 57(4), 225–241.

Fidler, I. (2003). The pathogenesis of cancer metastasis: the ‘seed and soil’ hypothesis revisited. Nature Reviews. Cancer, 3, 1–6.CrossRef

Paget, S. (1889). The distribution of secondary growth in cancer of breast. Lancet, 1, 98–101.

Ewing, J. (1919). Metastasis. In Neoplastic diseases (pp. 76–88). Philadelphia: Saunders.

Pienta, K. J., & Loberg, R. (2005). The ‘emigration, migration, and immigration’ of prostate cancer. Clinical Prostate Cancer, 4(1), 24–30.PubMedCrossRef

Norton, L. (1988). A Gompertzian model of human breast cancer growth. Cancer Research, 48, 7067–7071.PubMed

Zetter, B. (1998). Angiogenesis and tumor metastasis. Annual Review of Medicine, 49, 407–424.PubMedCrossRef

Wang, J., Loberg, R., & Taichman, R. S. (2006). The pivotal role of CXCL12 (SDF-1)/CXCR4 axis in bone metastasis. Cancer Metastasis Reviews, 25(4), 573–587.PubMedCrossRef

10.

Kortesidis, A., Zannettino, A., Isenmann, S., Shi, S., Lapidot, T., & Gronthos, S. (2005). Stromal-derived factor-1 promotes the growth, survival, and development of human bone marrow stromal stem cells. Blood, 105(10), 3793–3801.PubMedCrossRef

11.

Jung, Y., Wang, J., Schneider, A., Sun, Y.-X., Koh-Paige, A. J., Osman, N. I., et al. (2006). Regulation of SDF-1 (CXCL12) production by osteoblasts; a possible mechanism for stem cell homing. Bone, 38(4), 497–508.PubMedCrossRef

12.

Sun, Y., Fang, M., Wang, J., Cooper, C. R., Pienta, K. J., & Taichman, R. S., et al. (2007). Expression and Activation of a v b 3 Integrins by SDF-1 / CXC12 Increases the Aggressiveness of Prostate Cancer Cells. Prostate, 67(1), 61–73.

13.

Sun, Y.-X., Schneider, A., Jung, Y., Wang, J., Dai, J., Wang, J., et al. (2005). Skeletal localization and neutralization of the SDF-1(CXCL12)/CXCR4 axis blocks prostate cancer metastasis and growth in osseous sites in vivo. Journal of Bone and Mineral Research, 20(2), 318–329.PubMedCrossRef

14.

Havens, A. M., Jung, Y., Sun, Y. X., Wang, J., Shah, R., Bühring, H., et al. (2006). The role of sialomucin CD164 (MGC-24v or endolyn) in prostate cancer metastasis. BMC cancer, 6, 195.PubMedCentralPubMedCrossRef

15.

Jung, Y., Wang, J., Song, J., Shiozawa, Y., Wang, J., Havens, A., et al. (2007). Annexin II expressed by osteoblasts and endothelial cells regulates stem cell adhesion, homing, and engraftment following transplantation. Blood, 110(1), 82–90.PubMedCentralPubMedCrossRef

16.

Sikes, R. A., Nicholson, B. E., Koeneman, K. S., Edlund, N. M., Bissonette, E. A., Bradley, M. J., et al. (2004). Cellular interactions in the tropism of prostate cancer to bone. International Journal of Cancer, 110(4), 497–503.CrossRef

17.

Chung, L. W. K., Baseman, A., Assikis, V., & Zhau, H. E. (2005). Molecular insights into prostate cancer progression: the missing link of tumor microenvironment. The Journal of Urology, 173, 10–20.PubMedCrossRef

18.

Lipton, A. (2006). Future treatment of bone metastases. Clinical Cancer Research, 12(20 Pt 2), 6305s–6308s.PubMedCrossRef

19.

Mundy, G. R. (2002). Metastasis to bone: causes, consequences and therapeutic opportunities. Nature reviews. Cancer, 2(8), 584–593.PubMedCrossRef

20.

Loberg, R. D., Logothetis, C. J., Keller, E. T., & Pienta, K. J. (2005). Pathogenesis and treatment of prostate cancer bone metastases: targeting the lethal phenotype. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 23(32), 8232–8241.CrossRef

21.

Candelaria-Quintana, D., Dayao, Z. R., & Royce, M. E. (2012). The role of antiresorptive therapies in improving patient care in early and metastatic breast cancer. Breast cancer research and treatment, 132(2), 355–363.PubMedCrossRef

22.

Fornier, M. N. (2010). Denosumab: second chapter in controlling bone metastases or a new book? Journal of Clinical Oncology, 28(35), 5127–5131.PubMedCrossRef

23.

Ha, T. C., & Li, H. (2007). Meta-analysis of clodronate and breast cancer survival. British Journal of Cancer, 96(12), 1796–1801.PubMedCentralPubMedCrossRef

24.

Wu, S., Dahut, W. L., & Gulley, J. L. (2007). The use of bisphosphonates in cancer patients. Acta Oncologica, 46(5), 581–591.PubMedCrossRef

25.

Saad, F., Gleason, D. M., Murray, R., Tchekmedyian, S., Venner, P., Lacombe, L., et al. (2004). Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. Journal of the National Cancer Institute, 96(11), 879–882.PubMedCrossRef

26.

Lüftner, D., Henschke, P., & Possinger, K. (2007). Clinical value of bisphosphonates in cancer therapy. Anticancer research, 27(4A), 1759–1768.PubMed

27.

Schwarz, E. M., & Ritchlin, C. T. (2007). Clinical development of anti-RANKL therapy. Arthritis Research & Therapy, 9(Suppl 1), S7.CrossRef

28.

Tsourdi, E., Rachner, T. D., Rauner, M., Hamann, C., & Hofbauer, L. C. (2011). Denosumab for bone diseases: translating bone biology into targeted therapy. European Journal of Endocrinology, 165(6), 833–840.PubMedCrossRef

29.

Miyazaki, T., Tanaka, S., Sanjay, A., & Baron, R. (2006). The role of c-Src kinase in the regulation of osteoclast function. Modern Rheumatology, 16(2), 68–74.PubMedCrossRef

30.

Huang, F., Reeves, K., Han, X., Fairchild, C., Platero, S., Wong, T. W., et al. (2007). Identification of candidate molecular markers predicting sensitivity in solid tumors to dasatinib: rationale for patient selection. Cancer research, 67(5), 2226–2238.PubMedCrossRef

31.

Vandyke, K., Dewar, A. L., Diamond, P., Fitter, S., Schultz, C. G., Sims, N. A., et al. (2010). The tyrosine kinase inhibitor dasatinib dysregulates bone remodeling through inhibition of osteoclasts in vivo. Journal of Bone and Mineral Research, 25(8), 1759–1770.PubMedCrossRef

32.

Ritchie, C. K., Andrews, L. R., Thomas, K. G., Tindall, D. J., & Fitzpatrick, L. A. (1997). The effects of growth factors associated with osteoblasts on prostate carcinoma proliferation and chemotaxis : implications for the development of metastatic disease. Endocrinology, 138(3), 1145–1150.PubMed

33.

Zangari, M., Esseltine, D., Lee, C.-K., Barlogie, B., Elice, F., Burns, M. J., et al. (2005). Response to bortezomib is associated to osteoblastic activation in patients with multiple myeloma. British Journal of Haematology, 131, 71–73.PubMedCrossRef

34.

Terpos, E., Heath, D. J., Rahemtulla, A., Zervas, K., Chantry, A., Anagnostopoulos, A., et al. (2006). Bortezomib reduces serum dickkopf-1 and receptor activator of nuclear factor-kB ligand concentrations and normalises indices of bone remodelling in patients with relapsed multiple myeloma. British Journal of Haematology, 135(5), 688–692.PubMedCrossRef

35.

Vessella, R. L., & Corey, E. (2006). Targeting factors involved in bone remodeling as treatment strategies in prostate cancer bone metastasis. Clinical Cancer Research, 12(20 Pt 2), 6285s–6290s.PubMedCrossRef

36.

Chauhan, D., Hideshima, T., Mitsiades, C., Richardson, P., & Anderson, K. C. (2005). Proteasome inhibitor therapy in multiple myeloma. Molecular Cancer Therapeutics, 4(4), 686–692.PubMedCrossRef

37.

Kane, R. C., Dagher, R., Farrell, A., Ko, C.-W., Sridhara, R., Justice, R., et al. (2007). Bortezomib for the treatment of mantle cell lymphoma. Clinical Cancer Research, 13(18 Pt 1), 5291–5294.PubMedCrossRef

38.

Sartor, O. (2004). Overview of samarium Sm 153 lexidronam in the treatment of painful metastatic bone disease. Reviews in Urology, 6(Suppl 10), S3–S12.PubMedCentralPubMed

39.

Porter, A. T., McEwan, A. J., Powe, J. E., Reid, R., McGowan, D. G., Lukka, H., et al. (1993). Results of a randomized phase-III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer. Int. J. Radiation Oncology Biol. Phys., 25, 805–813.CrossRef

40.

Baczyk, M., Czepczyński, R., Milecki, P., Pisarek, M., Oleksa, R., & Sowiński, J. (2007). 89Sr versus 153Sm-EDTMP: comparison of treatment efficacy of painful bone metastases in prostate and breast carcinoma. Nuclear Medicine Communications, 28(4), 245–250.PubMedCrossRef

41.

Bauman, G., Charette, M., Reid, R., & Sathya, J. (2005). Radiopharmaceuticals for the palliation of painful bone metastases—a systematic review. Radiotherapy and Oncology, 75(3), 258. E1–258.E13.PubMedCrossRef

42.

Akerley, W., Butera, J., Wehbe, T., Noto, R., Stein, B., Safran, H., et al. (2002). A multiinstitutional, concurrent chemoradiation trial of strontium-89, estramustine, and vinblastine for hormone refractory prostate carcinoma involving bone. Cancer, 94(6), 1654–1660.PubMedCrossRef

43.

Tu, S. M., Millikan, R. E., Mengistu, B., Delpassand, E. S., Amato, R. J., Pagliaro, L. C., et al. (2001). Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomised phase II trial. Lancet, 357, 336–341.PubMedCrossRef

44.

Harrison, M. R., Wong, T. Z., Armstrong, A. J., & George, D. J. (2013). Radium-223 chloride: a potential new treatment for castration-resistant prostate cancer patients with metastatic bone disease. Cancer Management and Research, 5, 1–14.PubMedCentralPubMedCrossRef

45.

Rao, K. V. (2007). Lenalidomide in the treatment of multiple myeloma. American Journal of Health-System Pharmacy, 64(17), 1799–1807.PubMedCrossRef

46.

Murakami, H., Handa, H., Abe, M., Iida, S., Ishii, A., Ishikawa, T., et al. (2007). Low-dose thalidomide plus low-dose dexamethasone therapy in patients with refractory multiple myeloma. European Journal of Haematology, 79(3), 234–239.PubMedCrossRef

47.

Hicklin, D. J., & Ellis, L. M. (2005). Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. Journal of Clinical Oncology, 23(5), 1011–1027.PubMedCrossRef

48.

Chinot, O. L. (2012). Bevacizumab-based therapy in relapsed glioblastoma: rationale and clinical experience to date. Expert Review of Anticancer Therapy, 12(11), 1413–1427.PubMedCrossRef

49.

Flaherty, K. T. (2007). Sorafenib: delivering a targeted drug to the right targets. Expert Review of Anticancer Therapy, 7(5), 617–626.PubMedCrossRef

50.

Pantuck, A. J., Zomorodian, N., & Belldegrun, A. S. (2006). Phase I, open-label, single-center, multiple-dose, dose-escalation clinical study of SUO11248 (sunitinib) in subjects with high-risk prostate cancer who have elected to undergo radical prostatectomy. Clinical Cancer Research, 12, 4018–4026.PubMedCrossRef

51.

Drevs, J., Zirrgiebel, U., Schmidt-Gersbach, C. I. M., Mross, K., Medinger, M., Lee, L., et al. (2005). Soluble markers for the assessment of biological activity with PTK787/ZK 222584 (PTK/ZK), a vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor in patients with advanced colorectal cancer from two phase I trials. Annals of Oncology, 16(4), 558–565.PubMedCrossRef

52.

Smith, D. C., Smith, M. R., Sweeney, C., Elfiky, A. A., Logothetis, C., Corn, P. G., et al. (2013). Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial. Journal of Clinical Oncology, 31(4), 412–419.PubMedCrossRef

53.

Eskens, F. A. L. M., Dumez, H., Hoekstra, R., Perschl, A., Brindley, C., Böttcher, S., et al. (2003). Phase I and pharmacokinetic study of continuous twice weekly intravenous administration of cilengitide (EMD 121974), a novel inhibitor of the integrins αvβ3 and αvβ5 in patients with advanced solid tumours. European Journal of Cancer, 39(7), 917–926.PubMedCrossRef

54.

Mullamitha, S. A., Ton, N. C., Parker, G. J. M., Jackson, A., Julyan, P. J., Roberts, C., et al. (2007). Phase I evaluation of a fully human anti-alphav integrin monoclonal antibody (CNTO 95) in patients with advanced solid tumors. Clinical Cancer Research, 13(7), 2128–2135.PubMedCrossRef

55.

Tucker, G. C. (2006). Integrins: molecular targets in cancer therapy. Current Oncology Reports, 8(2), 96–103.PubMedCrossRef

56.

Gramoun, A., Shorey, S., Bashutski, J. D., Dixon, S. J., Sims, S. M., Heersche, J. N. M., et al. (2007). Effects of vitaxin, a novel therapeutic in trial for metastatic bone tumors, on osteoclast functions in vitro. Journal of Cellular Biochemistry, 102(2), 341–352.PubMedCrossRef

57.

Mulgrew, K., Kinneer, K., Yao, X.-T., Ward, B. K., Damschroder, M. M., Walsh, B., et al. (2006). Direct targeting of alphavbeta3 integrin on tumor cells with a monoclonal antibody, Abegrin. Molecular Cancer Therapeutics, 5(12), 3122–3129.PubMedCrossRef

58.

Cheever, M. A., & Higano, C. S. (2011). PROVENGE (sipuleucel-T) in prostate cancer: the first FDA-approved therapeutic cancer vaccine. Clinical Cancer Research, 17(11), 3520–3526.PubMedCrossRef

59.

Kantoff, P. W., Higano, C. S., Shore, N. D., Berger, E. R., Small, E. J., Penson, D. F., et al. (2010). Sipuleucel-T immunotherapy for castration-resistant prostate cancer. New England Journal of Medicine, 363(5), 411–422.PubMedCrossRef

60.

So-Rosillo, R., & Small, E. J. (2006). Sipuleucel-T (APC8015) for prostate cancer. Expert Review of Anticancer Therapy, 6(9), 1163–1167.PubMedCrossRef

61.

Park, J. W., Melisko, M. E., Esserman, L. J., Jones, L. A., Wollan, J. B., & Sims, R. (2007). Treatment with autologous antigen-presenting cells activated with the HER-2-based antigen lapuleucel-T: results of a phase I study in immunologic and clinical activity in HER-2 overexpressing breast cancer. Journal of Clinical Oncology, 25(24), 3680–3687.PubMedCrossRef

62.

de Gruijl, T. D., van den Eertwegh, A. J. M., Pinedo, H. M., & Scheper, R. J. (2008). Whole-cell cancer vaccination: from autologous to allogeneic tumor- and dendritic cell-based vaccines. Cancer Immunology, Immunotherapy, 57(10), 1569–1577.PubMedCentralPubMedCrossRef

63.

Kantoff, P. W., Schuetz, T. J., Blumenstein, B. A., Glode, L. M., Bilhartz, D. L., Wyand, M., et al. (2010). Overall survival analysis of a phase II randomized controlled trial of a poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. Journal of Clinical Oncology, 28(7), 1099–1105.PubMedCentralPubMedCrossRef

64.

Dayyani, F., Gallick, G. E., Logothetis, C. J., & Corn, P. G. (2011). Novel therapies for metastatic castrate-resistant prostate cancer. Journal of the National Cancer Institute, 103(22), 1665–1675.PubMedCrossRef

65.

Reck, M., Bondarenko, I., Luft, A., Serwatowski, P., Barlesi, F., Chacko, R., et al. (2013). Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial. Annals of Oncology, 24(1), 75–83.PubMedCrossRef

66.

Margolin, K., Ernstoff, M. S., Hamid, O., Lawrence, D., McDermott, D., Puzanov, I., et al. (2012). Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. The Lancet Oncology, 13(5), 459–465.PubMedCrossRef

67.

Sun, J., Schiffman, J., Raghunath, A., Ng Tang, D., Chen, H., & Sharma, P. (2008). Concurrent decrease in IL-10 with development of immune-related adverse events in a patient treated with anti-CTLA-4 therapy. Cancer Immunity, 8, 9–15.PubMedCentralPubMed

68.

Fulton, A., Miller, F., Weise, A., & Wei, W.-Z. (2007). Prospects of controlling breast cancer metastasis by immune intervention. Breast Disease, 26, 115–127.

69.

Melero, I., Grimaldi, A. M., Perez-Gracia, J. L., & Ascierto, P. A. (2013). Clinical development of immunostimulatory monoclonal antibodies and opportunities for combination. Clinical cancer research : an official journal of the American Association for Cancer Research, 19(5), 997–1008.CrossRef

70.

Fishelson, Z., Donin, N., Zell, S., Schultz, S., & Kirschfink, M. (2003). Obstacles to cancer immunotherapy: expression of membrane complement regulatory proteins (mCRPs) in tumors. Molecular Immunology, 40, 109–123.PubMedCrossRef

71.

Pritchard-Jones, K., Spendlove, I., Wilton, C., Whelan, J., Weeden, S., Lewis, I., et al. (2005). Immune responses to the 105 AD7 human anti-idiotypic vaccine after intensive chemotherapy, for osteosarcoma. British Journal of Cancer, 92(8), 1358–1365.PubMedCentralPubMedCrossRef

72.

Liao, Y., Schaue, D., & McBride, W. (2007). Modification of the tumor microenvironment to enhance immunity. Frontiers in Bioscience, 12, 3576–3600.PubMedCrossRef

73.

Dirkx, A. E. M., Oude Egbrink, M. G. A., Wagstaff, J., & Griffioen, A. W. (2006). Monocyte/macrophage infiltration in tumors: modulators of angiogenesis. Journal of Leukocyte Biology, 80(6), 1183–1196.PubMedCrossRef

74.

Lewis, C. E., & Pollard, J. W. (2006). Distinct role of macrophages in different tumor microenvironments. Cancer Research, 66(2), 605–612.PubMedCrossRef

75.

Bingle, L., Brown, N. J., & Lewis, C. E. (2002). The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies. Journal of Pathology, 196, 254–265.PubMedCrossRef

76.

Sica, A., Schioppa, T., Mantovani, A., & Allavena, P. (2006). Tumour-associated macrophages are a distinct M2 polarised population promoting tumour progression: potential targets of anti-cancer therapy. European Journal of Cancer, 42(6), 717–727.PubMedCrossRef

77.

Mantovani, A., Schioppa, T., Porta, C., Allavena, P., & Sica, A. (2006). Role of tumor-associated macrophages in tumor progression and invasion. Cancer Metastasis Reviews, 25(3), 315–322.PubMedCrossRef

78.

Porta, C., Kumar, B. S., Larghi, P., Rubino, L., Mancino, A., & Sica, A. (2007). Tumor promotion by tumor-associated macrophages. Advances in Experimental Medicine and Biology, 604, 67–86.PubMedCrossRef

79.

Loberg, R. D., Ying, C., Craig, M., Yan, L., Snyder, L. A., & Pienta, K. J. (2007). CCL2 as an important mediator of prostate cancer growth in vivo through the regulation of macrophage infiltration. Neoplasia, 9(7), 556–562.PubMedCentralPubMedCrossRef

80.

Bailey, C., Negus, R., Morris, A., Ziprin, P., Goldin, R., Allavena, P., et al. (2007). Chemokine expression is associated with the accumulation of tumour associated macrophages (TAMs) and progression in human colorectal cancer. Clinical & Experimental Metastasis, 24(2), 121–130.CrossRef

81.

Craig, M. J., & Loberg, R. D. (2006). CCL2 (monocyte chemoattractant protein-1) in cancer bone metastases. Cancer Metastasis Reviews, 25(4), 611–619.PubMedCrossRef

82.

Pienta, K. J., Machiels, J.-P., Schrijvers D., Alekseev B., M. Shkolnik, & Crabb, S. J., et al. (2013). Phase 2 study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 (CCL2), in metastatic castration-resistant prostate cancer. Invest New Drugs, 31(3), 760–768.

83.

Sandhu, S. K., Papadopoulos, K., Fong, P. C., Patnaik, A., Messiou, C., Olmos, D., et al. (2013). A first-in-human, first-in-class, phase I study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 in patients with solid tumors. Cancer Chemotherapy and Pharmacology, 71(4), 1041–1050.PubMedCrossRef

84.

Baay, M., Brouwer, A., Pauwels, P., Peeters, M., & Lardon, F. (2011). Tumor Cells and Tumor-Associated Macrophages: Secreted Proteins as Potential Targets for Therapy. Clinical & Developmental Immunology, p. 565187.

85.

Petit, I., Szyper-Kravitz, M., Nagler, A., Lahav, M., Peled, A., Habler, L., et al. (2002). G-CSF induces stem cell mobilization by decreasing bone marrow SDF-1 and up-regulating CXCR4. Nature Immunology, 3(7), 687–694.PubMedCrossRef

86.

Shiozawa, Y., Pedersen, E. A., Havens, A. M., Jung, Y., Mishra, A., Joseph, J., et al. (2011). Human prostate cancer metastases target the hematopoietic stem cell niche to establish footholds in mouse bone marrow. Journal of Clinical Investigation, 121(4), 1298–1312.PubMedCentralPubMedCrossRef

87.

Smith, M. C. P., Luker, K. E., Garbow, J. R., Prior, J. L., Jackson, E., Piwnica-Worms, D., et al. (2004). CXCR4 regulates growth of both primary and metastatic breast cancer. Cancer Research, 64(23), 8604–8612.PubMedCrossRef

88.

Meads, M. B., Hazlehurst, L. A., & Dalton, W. S. (2008). The bone marrow microenvironment as a tumor sanctuary and contributor to drug resistance. Clinical Cancer Research, 14(9), 2519–2526.PubMedCrossRef

89.

Vincent, T., & Mechti, N. (2005). Extracellular matrix in bone marrow can mediate drug resistance in myeloma. Leukemia & Lymphoma, 46(6), 803–811.CrossRef

90.

Camacho, D. F., & Pienta, K. J. (2012). Disrupting the networks of cancer. Clinical Cancer Research, 18(10), 2801–2808.PubMedCrossRef

91.

Chen, K. W., & Pienta, K. J. (2011). Modeling invasion of metastasizing cancer cells to bone marrow utilizing ecological principles. Theoretical Biology and Medical Modeling, 8(36), 1–11.

Title: A multi-targeted approach to treating bone metastases
Authors: Daniel F. Camacho
Kenneth J. Pienta
Publication date: 01-09-2014
Publisher: Springer US
Published in: Cancer and Metastasis Reviews / Issue 2-3/2014
Print ISSN: 0167-7659
Electronic ISSN: 1573-7233
DOI: https://doi.org/10.1007/s10555-013-9476-y

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2-3/2014

Androgen receptor signaling in prostate cancer

Emerging technology: applications of Raman spectroscopy for prostate cancer

Advances in genomic characterization of circulating tumor cells

Novel drugs targeting the androgen receptor pathway in prostate cancer

Growth factor and signaling pathways and their relevance to prostate cancer therapeutics

The role of epithelial plasticity in prostate cancer dissemination and treatment resistance

Keynote webinar | Spotlight on antibody–drug conjugates in cancer